Summary
The Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome [JOQUER; NCT00632866] trial found no significant difference in the evolution of systemic disease activity, dryness, symptoms, and quality of life in patients treated with hydroxychloroquine when compared with placebo.
- Rheumatology Clinical Trials
- Rheumatological Autoimmune Disorders
- © 2012 MD Conference Express®
Tools
Inefficacy of Hydroxychoroquine in Primary Sjögren's Syndrome: Results of the JOQUER Trial
Permalink:
Table of contents
Cited By...
- No citing articles found.